Se ob

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D C 20549

eck this box if no longer subject to	STATEMENT OF CHANGE
ction 16. Form 4 or Form 5	
ligations may continue. See	

S IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response 0.5

See

footnote(2)

footnote(3) See

footnote(4)

Instruction 1(b) Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer 1. Name and Address of Reporting Person* Allogene Therapeutics, Inc. [ALLO] (Check all applicable) Chang David D Directo 10% Owner Officer (give title Other (specify 3. Date of Earliest Transaction (Month/Day/Year) X below) below) (Last) (First) (Middle) 03/22/2023 President and CEO 210 EAST GRAND AVENUE 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person SOUTH SAN Form filed by More than One Reporting Person 94080 CA **FRANCISCO** Rule 10b5-1(c) Transaction Indication (City) (State) (Zip) Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 2. Transaction 2A. Deemed Execution Date. 7. Nature of 1. Title of Security (Instr. 3) 5. Amount of Securities 6. Ownership Form: Direct Transaction Indirect Beneficially Owned Following (D) or Indire (I) (Instr. 4) Beneficial (Month/Day/Year Code (Instr. 8) Ownership (Instr. 4) Reported (A) or (D) Transaction(s) ν Price Code Amount (Instr. 3 and 4) Common Stock 03/22/2023 1,924,464(1) \$<mark>0</mark> 4,193,911 D A

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 7. Title and Amount of Securities Underlying 1. Title of 3. Transaction 3A. Deemed . Number of 6. Date Exercisable and 8. Price of 9. Number of 10. 11. Nature Conversion Derivative Execution Date Transaction Derivative **Expiration Date** Derivative derivative Ownership of Indirect Security (Instr. 3) or Exercise Price of Securities Acquired (A) Derivative Security (Instr. 3 and 4) Securities Beneficially Form: Direct (D) or Indirect Beneficial Ownership (Month/Day/Year) if any (Month/Day/Year) Code (Instr. 8) (Month/Day/Year) Security (Instr. 5) or Disposed of (D) (Instr. 3, 4 and 5) Derivative Owned (Instr. 4) Following Reported Transaction(s) (Instr. 4) (I) (Instr. 4) Security Amount or Number of Expiration Date Code v (A) (D) Exercisable Title Shares Stock Option (Right to \$5.04 03/22/2023 1.492.200 (5) 03/22/2033 1,492,200 **\$0** 1.492.200 D Stock

Explanation of Responses:

Common Stock

Common Stock

Common Stock

- 1. Includes 1,480,357 of performance RSUs which shall vest as follows: (1) 50% shall vest if the 30-day weighted average stock price is equal to or greater than \$18 and (2) 50% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated after three years from the grant date if such threshold has not been met in such three-year period, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after five years from the grant date if such approval has not occurred in such
- 2. Securities held in the name of the Chang 2006 Family Trust
- 3. Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
- 4. Securities held in the name of the RTC 2019 Trust dated October 1, 2019.
- 5. 25% of the shares subject to the stock option shall vest on March 13, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.

Remarks:

/s/Veer Bhavnagri, Attorney-in-03/24/2023 Fact

** Signature of Reporting Person

Date

1,201,108

856,044

856,044

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.